Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference
Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.
Cidara Therapeutics, Inc.（納斯達克股票代碼：CDTX）是一家利用其專有的Cloudbreak平台開發藥物-FC偶聯物（DFC）免疫療法的生物技術公司（納斯達克股票代碼：CDTX）今天宣佈在將於2024年9月29日至10月2日在澳大利亞布里斯班舉行的流感控制會議OPTIONS XII上發表兩場演講。這些演講包括一份口頭報告和一份海報，將重點介紹西達拉流感藥物-FC偶聯物（DFC）候選藥物 CD388 臨床研究的安全性和藥代動力學（PK）數據。